Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 3, 2015, Pages 298-306

  Olagunju, A ^a,b   Bolaji, O ^b   Amara, A ^a   Else, L ^a   Okafor, O ^c   Adejuyigbe, E ^b   Oyigboja, J ^d   Back, D ^a   Khoo, S ^a   Owen, A ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^c Bishop Murray Medical Centre   (Nigeria)

^d Justice Development and Peace Commission   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CYTOCHROME P450 2B6; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE; ABCB1 PROTEIN, HUMAN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CELL RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYP2A6 PROTEIN, HUMAN; CYP2B6 PROTEIN, HUMAN; CYTOCHROME P450 2A6; MULTIDRUG RESISTANCE PROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM CONCENTRATION; PHARMACOGENETICS; PHARMACOKINETIC PARAMETERS; PREGNANCY; PRIORITY JOURNAL; CASE CONTROL STUDY; GENETICS; HOMOZYGOTE; PUERPERIUM; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2A6; CYTOCHROME P-450 CYP2B6; FEMALE; HOMOZYGOTE; HUMANS; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTPARTUM PERIOD; PREGNANCY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; YOUNG ADULT;

EID: 84927686006     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.43     Document Type: Article

References (48)

1. World Health Organization. PMTCT strategic vision 2010-2015. Preventing mother-to-child transmission of HIV to reach the UNGASS and Millennium Development Goals . Accessed 30 September 2014.
2. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection . Accessed 30 September 2014.
3. Centers for Disease Control and Prevention. Impact of an innovative approach to prevent mother-to-child transmission of HIV – Malawi, July 2011–September 2012. MMWR Morb. Mortal. Wkly. Rep. 62, 148–151 (2013).
4. World Health Organization. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: programmatic update . Accessed 30 September 2014.
5. World Health Organization. Global HIV/AIDS response. Epidemic update and health sector progress towards universal access: progress report 2011 . Accessed 25 July 2014.
6. Anderson, G.D. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin. Pharmacokinet. 44, 989–1008 (2005).
7. Best, B.M. & Goicoechea, M. Efavirenz — Still first-line king? Expert Opin. Drug Metab. Toxicol. 4, 965–972 (2008).
8. Cressey, T.R. et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J. Acquir. Immune Defic. Syndr. 59, 245–252 (2012).
9. Benaboud, S. et al. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrob. Agents Chemother. 56, 776–782 (2012).
10. Best, B.M. et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS 20, 553–560 (2006).
11. Stek, A.M. et al. Reduced lopinavir exposure during pregnancy. AIDS 20, 1931–1939 (2006).
12. Lamorde, M. et al. Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women. J. Acquir. Immune Defic. Syndr. 55, 345–350 (2010).
13. Stek, A.M. et al. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med. 13, 226–235 (2012).
14. Benaboud, S. et al. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Antimicrob. Agents Chemother. 56, 857–862 (2012).
15. Mirochnick, M. et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J. Acquir. Immune Defic. Syndr. 56, 412–419 (2011).
16. Cressey, T.R. et al. Reduced indinavir exposure during pregnancy. Br. J. Clin. Pharmacol. 76, 475–483 (2013).
17. Buckoreelall, K., Cressey, T.R. & King, J.R. Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin. Pharmacokinet. 51, 639–659 (2012).
18. Mirochnick, M. & Capparelli, E. Pharmacokinetics of antiretrovirals in pregnant women. Clin. Pharmacokinet. 43, 1071–1087 (2004).
19. Olagunju, A., Owen, A. & Creesey, T.R. Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. Pharmacogenomics 13, 1501–1522 (2012).
20. Blehar, M.C., Spong, C., Grady, C., Goldkind, S.F., Sahin, L. & Clayton, J.A. Enrolling pregnant women: issues in clinical research. Womens Health Issues 23, e39–45 (2013).
21. Ward, B.A., Gorski, J.C., Jones, D.R., Hall, S.D., Flockhart, D.A. & Desta, Z. The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306, 287–300 (2003).
22. Sarfo, F.S. et al. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J. Antimicrob. Chemother. 69, 491–499 (2014).
23. Wyen, C. et al. Impact of CYP2B6 983T > C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J. Antimicrob. Chemother. 61, 914–918 (2008).
24. Swart, M., Skelton, M., Ren, Y., Smith, P., Takuva, S. & Dandara, C. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenet. Genomics 23, 415–427 (2013).
25. Holzinger, E.R. et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet. Genomics 22, 858–867 (2012).
26. Kwara, A., Lartey, M., Sagoe, K.W.C., Kenu, E. & Court, M.H. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 23, 2101–2106 (2009).
27. Swart, M., Whitehorn, H., Ren, Y., Smith, P., Ramesar, R.S. & Dandara, C. PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients. BMC Med. Genet. 13, 112 (2012).
28. Fellay, J. et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359, 30–36 (2002).
29. Kappelhoff, B.S., Crommentuyn, K.M., de Maat, M.M., Mulder, J.W., Huitema, A.D. & Beijnen, J.H. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin. Pharmacokinet. 43, 845–853 (2004).
30. Marzolini, C., Telenti, A., Decosterd, L.A., Greub, G., Biollaz, J. & Buclin, T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15, 71–75 (2001).
31. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents . Accessed 2 September 2014.
32. Langmann, P. et al. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients. Eur. J. Med. Res. 7, 309–314 (2002).
33. Dickinson, L. & Puls, R. Efavirenz (EFV) 400 versus 600 mg daily: Results of the ENCORE1 intensive PK substudy [abstract 510]. Top. Antivir. Med. 22, 244–245 (2014).
34. Puls, R.L. et al. Efficacy of 400 mg efavirenz vs. standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet 383, 1474–1482 (2014).
35. Hofmann, M.H. et al. Aberrant splicing caused by single nucleotide polymorphism c.516G > T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J. Pharmacol. Exp. Ther. 325, 284–292 (2008).
36. Habtewold, A. et al. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. Antimicrob. Agents Chemother. 66, 2350–2361 (2011).
37. Koh, K.H. et al. Estradiol induces cytochrome P450 2B6 expression at high concentrations: implication in estrogen-mediated gene regulation in pregnancy. Biochem. Pharmacol. 84, 93–103 (2012).
38. Amara, A.B. et al. A validated method for quantification of efavirenz in dried blood spots (DBS) using HPLC-MS/MS. Ther. Drug Monit. (2014); published online 26 August (doi: 10.1097/FTD.0000000000000127).
39. Kromdijk, W., Mulder, J.W., Rosing, H., Smit, P.M., Beijnen, J.H. & Huitema, A.D. Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz. J. Antimicrob. Chemother. 67, 1211–1216 (2012).
40. Bartelink, I.H. et al. Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda. J. Clin. Pharmacol. 54, 121–132 (2014).
41. Dooley, K.E. et al. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis co-infection. J. Infect. Dis. (2014); published online 31 July (doi: 10.1093/infdis/jiu429).
42. Flicek, P. et al. Ensembl 2013. Nucleic Acids Res. 41, D48–55 (2013).
43. van der Baan, F.H., Knol, M.J., Klungel, O.H., Egberts, A.C., Grobbee, D.E. & Roes, K.C. Potential of adaptive clinical trial designs in pharmacogenetic research. Pharmacogenomics 13, 571–478 (2012).
44. Temple, R. Enrichment of clinical study populations. Clin. Pharmacol. Ther. 88, 774–778 (2010).
45. Persaud, D. et al. Functional HIV cure after very early ART of an infected infant [abstract 48LB]. In: Program and abstracts of the Conference on Retroviruses and Opportunistic Infections (2013).
46. Martin, A.S. et al. Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics. Pharmacogenomics 15, 997–1006 (2014).
47. Lundgren, J.D. & Phillips, A. Antiretroviral dose reduction: good for patients and rollout. Lancet 383, 1442–1443 (2014).
48. Rodriguez, S., Gaunt, T.R. & Day, I.N. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am. J. Epidemiol. 169, 505–514 (2009).